Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00324361 | Colorectum | SER | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 32/2897 | 90/18723 | 2.23e-06 | 9.31e-05 | 32 |
GO:00525481 | Colorectum | SER | regulation of endopeptidase activity | 103/2897 | 432/18723 | 2.86e-06 | 1.16e-04 | 103 |
GO:00071631 | Colorectum | SER | establishment or maintenance of cell polarity | 60/2897 | 218/18723 | 3.45e-06 | 1.33e-04 | 60 |
GO:00329841 | Colorectum | SER | protein-containing complex disassembly | 61/2897 | 224/18723 | 4.17e-06 | 1.60e-04 | 61 |
GO:00610081 | Colorectum | SER | hepaticobiliary system development | 45/2897 | 150/18723 | 4.98e-06 | 1.85e-04 | 45 |
GO:00109521 | Colorectum | SER | positive regulation of peptidase activity | 55/2897 | 197/18723 | 5.44e-06 | 2.00e-04 | 55 |
GO:00018891 | Colorectum | SER | liver development | 44/2897 | 147/18723 | 6.73e-06 | 2.35e-04 | 44 |
GO:00432811 | Colorectum | SER | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 57/2897 | 209/18723 | 8.08e-06 | 2.74e-04 | 57 |
GO:00161971 | Colorectum | SER | endosomal transport | 61/2897 | 230/18723 | 1.03e-05 | 3.35e-04 | 61 |
GO:20001161 | Colorectum | SER | regulation of cysteine-type endopeptidase activity | 62/2897 | 235/18723 | 1.05e-05 | 3.39e-04 | 62 |
GO:00719851 | Colorectum | SER | multivesicular body sorting pathway | 17/2897 | 37/18723 | 1.12e-05 | 3.60e-04 | 17 |
GO:00359661 | Colorectum | SER | response to topologically incorrect protein | 46/2897 | 159/18723 | 1.14e-05 | 3.63e-04 | 46 |
GO:19030081 | Colorectum | SER | organelle disassembly | 36/2897 | 114/18723 | 1.22e-05 | 3.89e-04 | 36 |
GO:00091521 | Colorectum | SER | purine ribonucleotide biosynthetic process | 48/2897 | 169/18723 | 1.27e-05 | 4.01e-04 | 48 |
GO:00325091 | Colorectum | SER | endosome transport via multivesicular body sorting pathway | 15/2897 | 31/18723 | 1.70e-05 | 5.11e-04 | 15 |
GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
GO:00359671 | Colorectum | SER | cellular response to topologically incorrect protein | 36/2897 | 116/18723 | 1.88e-05 | 5.51e-04 | 36 |
GO:00160421 | Colorectum | SER | lipid catabolic process | 77/2897 | 320/18723 | 3.52e-05 | 9.18e-04 | 77 |
GO:00316671 | Colorectum | SER | response to nutrient levels | 106/2897 | 474/18723 | 3.94e-05 | 1.00e-03 | 106 |
GO:00092601 | Colorectum | SER | ribonucleotide biosynthetic process | 49/2897 | 182/18723 | 4.85e-05 | 1.19e-03 | 49 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CP | SNV | Missense_Mutation | novel | c.1843N>A | p.Gln615Lys | p.Q615K | P00450 | protein_coding | tolerated(0.28) | possibly_damaging(0.521) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
CP | SNV | Missense_Mutation | | c.204G>T | p.Lys68Asn | p.K68N | P00450 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
CP | SNV | Missense_Mutation | | c.2285A>C | p.Asn762Thr | p.N762T | P00450 | protein_coding | deleterious(0.04) | benign(0.061) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CP | SNV | Missense_Mutation | | c.1468N>C | p.Tyr490His | p.Y490H | P00450 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CP | SNV | Missense_Mutation | | c.616G>A | p.Asp206Asn | p.D206N | P00450 | protein_coding | tolerated(0.38) | benign(0.052) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CP | SNV | Missense_Mutation | | c.2254N>A | p.Glu752Lys | p.E752K | P00450 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CP | insertion | Nonsense_Mutation | novel | c.208_209insACTCATCGGACCTTTAATAATCTGTAAAAAAGGTACAT | p.Ala70AspfsTer6 | p.A70Dfs*6 | P00450 | protein_coding | | | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CP | SNV | Missense_Mutation | novel | c.224A>G | p.Tyr75Cys | p.Y75C | P00450 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CP | SNV | Missense_Mutation | | c.550N>A | p.Asp184Asn | p.D184N | P00450 | protein_coding | tolerated(0.09) | possibly_damaging(0.803) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CP | SNV | Missense_Mutation | | c.572N>T | p.Ser191Leu | p.S191L | P00450 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |